Indian pharmaceutical companies are significantly impacting the global weight loss drug market by introducing generic versions that reduce treatment costs by up to 70 percent.

Indian pharmaceutical companies are expressing significant concern and uncertainty following former President Donald Trump's proposal to impose tariffs, potentially up to 200%, on generic drug imports. Trump stated that non-patented drugmakers would have two years to move production to the U.S. or face a 100% import tariff, which would double a year later, severely impacting India's dominant position in the global generic drug market. Meanwhile, a Portuguese article discusses careerists in politics, using metaphors of bulls and horses to describe vitality, which is a separate topic.

Following the expiration of Novo's patent, Indian drugmakers are set to sell a copy of the diabetes and weight-loss drug Ozempic for approximately $14 a month, significantly cheaper than the original.